Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.

Employees

255

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 16:00:00 2025-02-20 EST			5-day change	1st Jan Change
20.01 ^USD	+0.25%		-.--%	-

04-28	Singular Genomics Appoints John Stark as Chief Executive Officer	CI
04-28	Singular Genomics Systems, Inc. Announces Transition of Josh Stahl as Independent Director	CI

Market Cap	49.23M 43.02M 39.7M 36.59M 68.97M 4.74B 70.5M 475M 187M 2.32B 185M 181M 7.99B	P/E 2022	-1.57x	P/E 2023	-0.35x
Enterprise Value	-50.88M -44.47M -41.03M -37.82M -71.28M -4.9B -72.87M -490M -193M -2.4B -191M -187M -8.26B	EV / Sales 2022	-56,007,684x	EV / Sales 2023	-22,792,100x
Free-Float	84.03%	Yield 2022 *	-	Yield 2023	-

04-28	Singular Genomics Appoints John Stark as Chief Executive Officer	CI
04-28	Singular Genomics Systems, Inc. Announces Transition of Josh Stahl as Independent Director	CI
03-18	Singular Genomics and Vanderbilt University Medical Center Establish Center of Excellence to Advance High-Throughput Spatial Multimodal Profiling in Gastric Pre-Cancer	CI
02-18	Singular Genomics Launches G4X in the U.S., Delivering Throughput for in Situ Multiomics, Targets Translational and Clinical Applications	CI
25-02-27	Singular Genomics Systems, Inc. Announces Management Changes	CI
25-02-27	Dalen Meeter Resigns as CFO of Singular Genomics Systems, Inc	CI
25-02-22	Singular Genomics Systems, Inc. Announces Board Changes	CI
25-02-22	Singular Genomics Systems, Inc. Announces Chief Executive Officer Changes	CI
25-02-20	Singular Genomics Systems, Inc.(NasdaqCM:OMIC) dropped from NASDAQ Composite Index	CI
25-02-20	Deerfield Mgmt IV, L.P., Deerfield Private Design Fund IV, L.P., funds managed by Deerfield Management Company, L.P. Series C, completed the acquisition of the remaining 93.4% stake in Singular Genomics Systems, Inc. from a group of shareholders.	CI
25-02-20	Singular Genomics Systems, Inc.(NasdaqCM:OMIC) dropped from S&P TMI Index	CI
24-12-23	Singular Genomics Systems Agrees to Be Acquired By Deerfield Management for $20 per Share	MT
24-11-12	Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Reports Q3 Revenue $0.4M	MT

24-07-09	Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $6.50 From $22.50, Maintains Neutral Rating	MT
24-05-15	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	MT
24-03-20	UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	MT
24-01-22	Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	MT
23-10-12	UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	MT

Singular Genomics Systems, Inc. Stock

Stocks

OMIC

US82933R3084

Advanced Medical Equipment & Technology

Valuation: Singular Genomics Systems, Inc.

Latest news : Singular Genomics Systems, Inc.

Analysts' recommendations: Singular Genomics Systems, Inc.

Press Releases: Singular Genomics Systems, Inc.

News in other languages: Singular Genomics Systems, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Singular Genomics Systems, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Income Statement and Estimates

25-02-24	Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT	AQ
25-02-21	Singular Genomics Announces Closing of Acquisition by Deerfield Management	AQ
25-01-21	SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC	BU
25-01-06	SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC	BU
24-12-23	Singular Genomics : Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share Form 8 K	PU

24-09-13	MÄRKTE USA/Weiter aufwärts - Goldpreis auf Allzeithoch
24-09-13	MÄRKTE USA/Weiter aufwärts - Adobe-Kurs knickt ein
24-09-13	MÄRKTE USA/Etwas fester - Spekulation über große Zinssenkung lebt wieder auf
24-09-13	MÄRKTE USA/Positive Stimmung an Wall Street dürfte anhalten
24-06-24	Borsa di Italia: L'Eurozona vuole evitare il suo momento Liz Truss

Manager	Title	Age	Since
John Stark CEO	Chief Executive Officer	-	2026-04-27
Jason W. Myers PSD	President	50	2025-02-20
Jyotsna Ghai COO	Chief Operating Officer	67	2023-08-31

Director	Title	Age	Since
Andrew Spaventa CHM	Chairman	41	2016-05-31
Joshua Stahl BRD	Director/Board Member	40	2025-02-20
Jason W. Myers BRD	Director/Board Member	50	2025-02-20

Date	Insider	Type	Main position	Quantity	% Market Cap.
2/21/25	Jason Ryan	Issuer sale	Director	7,806	0.3077%
2/21/25	Tang Capital Management LLC	Issuer sale	Company	372,000	14.6628%
2/21/25	Andrew Spaventa	Issuer sale	Founder	262,242	10.3366%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SINGULAR GENOMICS SYSTEMS, INC.	+0.25%	-.--%	-.--%	-29.79%	50.7M
THERMO FISHER SCIENTIFIC, INC.	-1.97%	+1.03%	+25.30%	+1.37%	198B
DANAHER CORPORATION	-0.58%	+2.40%	+4.64%	-14.27%	144B
INTUITIVE SURGICAL, INC.	-14.15%	-15.08%	-33.08%	-2.38%	122B
BOSTON SCIENTIFIC CORPORATION	-1.32%	-1.65%	-57.93%	-16.31%	65.44B
EDWARDS LIFESCIENCES CORPORATION	-2.40%	-7.03%	+12.54%	-7.47%	49.36B
SIEMENS HEALTHINEERS AG	-0.11%	+1.53%	-24.62%	-31.81%	44.75B
AGILENT TECHNOLOGIES, INC.	-3.41%	-2.11%	+12.98%	+11.17%	37.13B
WATERS CORPORATION	-2.44%	-1.98%	+24.27%	+36.75%	36.23B
GE HEALTHCARE TECHNOLOGIES INC.	-4.00%	-2.52%	-17.27%	-22.32%	28.69B
Average	-1.53%	-2.07%	-5.32%	-7.51%	72.61B
Weighted average by Cap.	-1.33%	-1.83%	-2.45%	-5.28%

	2022	2023
Net sales	0.76 0.67 0.62 0.57 1.07 73.67 1.1 7.37 2.9 36.08 2.87 2.81 124.21	2.91 2.54 2.35 2.16 4.08 280.33 4.17 28.06 11.04 137.3 10.93 10.69 472.64
Net income	-90.88M -79.42M -73.29M -67.55M -127M -8.75B -130M -876M -345M -4.29B -341M -334M -14.76B	-94.82M -82.86M -76.46M -70.48M -133M -9.13B -136M -914M -359M -4.47B -356M -348M -15.4B
Net Debt	-186M -163M -150M -139M -261M -17.95B -267M -1.8B -706M -8.79B -700M -684M -30.26B	-100M -87.49M -80.73M -74.41M -140M -9.64B -143M -965M -380M -4.72B -376M -368M -16.25B

3 years	5.34	30
5 years	5.34	610.5
10 years	5.34	1,001.1